ICSN3250 hydrochloride

  Cat. No.:  DC11151  
Chemical Structure
1561902-79-1
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.
Cas No.: 1561902-79-1
Chemical Name: 5,5'-(1-(3-(azacyclotridecan-1-yl)propyl)-1H-pyrrole-3,4-diyl)bis(3-nitrobenzene-1,2-diol) hydrochloride
Synonyms: ICSN-3250
SMILES: N(CCCN1CCCCCCCCCCCC1)1C=C(C2C=C(O)C(O)=C([N+]([O-])=O)C=2)C(C2C=C(O)C(O)=C([N+]([O-])=O)C=2)=C1.[H]Cl
Formula: C31H41ClN4O8
M.Wt: 633.139
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors; ICSN3250 is not a kinase inhibitor of mTOR, competes with and displaces phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity; displays no inhibitory capacity towards PI3Kα, β, γ, or δ; inhibits mTORC1 by following an unprecedented mechanism that involved its competition with PA at the FRB domain of mTOR to overcome the TSC negative regulation of mTORC1; ICSN3250 specifically targets cancer cells both in vitro and ex vivo.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47560 (32-Carbonyl)-RMC-5552 (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2).
DC47559 Dihydroevocarpine Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity.
DC47252 RMC-6272 RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.
DC44210 mTOR inhibitor-8 mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells.
DC5088 WYE125132 WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor
DC3101 Ku-0063794 KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM.
DC11150 ICSN3250 ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.
DC11151 ICSN3250 hydrochloride ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.
X